Psoriatic Arthritis during Treatment with Bevacizumab for Anaplastic Oligodendroglioma

  • Graceffa D
  • Maiani E
  • Pace A
  • et al.
N/ACitations
Citations of this article
6Readers
Mendeley users who have this article in their library.

Abstract

Bevacizumab is a recombinant humanised monoclonal antibody directed against the vascular endothelial growth factor (VEGF). The drug, alone or in combination with other anticancer agents, has been shown to be effective against several types of neoplasms. We report a case of a woman with a history of severe psoriasis who developed psoriatic arthritis during a course of bevacizumab, which was administered for a malignant glioma.

Cite

CITATION STYLE

APA

Graceffa, D., Maiani, E., Pace, A., Solivetti, F. M., Elia, F., De Mutiis, C., & Bonifati, C. (2012). Psoriatic Arthritis during Treatment with Bevacizumab for Anaplastic Oligodendroglioma. Case Reports in Rheumatology, 2012, 1–3. https://doi.org/10.1155/2012/208606

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free